papilledema in ophtalmoscopy. The prostate was normal on rectal examination.
Laboratory studies (Table I ) disclosed average anemia and thrombocytosis (572 x 10 9 /L), normal white blood cell count and their differential count, elevated ESR (63 mm). Routine blood chemistries, LDH, alkaline and acid phosphatase levels, liver and renal tests as well as β 2 microglobulin concentration were within normal values. A small spike in serum electrophoresis was identified as M component IgGλ, at a concentration of 0.8 g/dL (Figures 1AB). Urinalysis showed inconsiderable proteinuria -0.2 g/24h. HIV, hepatitis B and C markers were negative. PSA was normal. The X-ray examination of the skeleton revealed numerous mixed osteosclerotic and osteolytic lesions, with an evident predominance of the former ones within the skull, the ribs, the cervical and lumbar vertebra, the humerus, the femur, the pelvis and the sacrum (Figure 2 ). Ultrasound examination of the abdomen disclosed splenomegaly (165 mm) with no abnormalities in other organs such as the prostate and lymph nodes and no signs of ascites. Ultrasonography of the thyroid gland and cervical lymph nodes did not reveal and the platelet counts were below 700.0 x 10 9 /L. The patient's physical examination after six VAD courses (Table I ) revealed bone pain, neurological abnormalities and leg edema. Peripheral neuropathy was confirmed in the course of electromyographic examination (EMG) which showed signs of mixed demyelinizating and axonal degenerative neuropathy in the upper and lower extremities. Additionally discrete hypothyroidism with increased TSH and normal T3 and T4 concentrations was found. Bone marrow plasma cell rate was 5%. No progression of bone lesions was observed. Lymphadenopathy, splenomegaly, papilledema and thrombocytosis remained at the same level as at the onset of treatment.
Due to the lack of significant improvement, especially regarding the polyneuropathy symptoms, the patient underwent autologous PBSCT. Following G-CSF stimulation, 502 x 10 6 of CD34 + cells were collected. After myeloablative treatment with Melphalan 200 mg/d i.v. for two days, the autotransplantation of 2.3 x 10 6 CD34 + cells/kg was performed. Due to absence of haemopoiesis regeneration on day +12 and septicemia (Staphylococcus epidermidis) the patient received G-CSF and was transplanted with 2.0 x 10 6 CD34 + cells/kg on day +14. The platelet count was >20 x 10 9 /L on day +21 and >50 x 10 9 /L on day +27, while the white blood cell count exceeded 1.0 x 10 9 /L with the absolute neutrocyte count >0.5 x 10 9 /L on day +17. The patient was discharged from the Transplantation Ward with features of hematopoietic recovery. Control tests performed during his hospitalization in the Transplantation Ward and out-patient observation showed normalization of platelet count, persistence of serum M protein and splenomegaly, and appearance of a small amount of fluid in both the peritoneal and the pleural cavities. No relevant abnormalities were found in the course of echocardiography.
Status assessment performed 5.5 months after autologous PBSCT (Table I) showed the patient in good clinical condition, with diminishing bone pain, regression of leg edema and some subjective amelioration of motor functions. However, the EMG test did not show any improvement of the sensory and motor neuropathy within the extremities. Small palpable lymph nodes could also be discerned in the neck and the left axilla, with maintained splenomegaly and papilledema. Laboratory tests showed normal platelet count, slightly decreased leukocyte count (3.4 x 10 9 /L), mild anemia and normal β 2 microglobulin level. Serum M protein concentration was 0.8 g/dL ( Figures 1CD). A small amount of monoclonal protein IgGλ (42 mg/dL; total 0.53g/24 h) was detected in urine by immunofixation. Plasma cell rate in bone marrow biopsy was 3%. Thyroid hormone profile showed elevated TSH concentration. No progression of osteosclerotic and osteolytic lesions was found in X-ray examination of the skeleton. Abdominal ultrasonography disclosed splenomegaly of 155 mm and a small amount of fluid in the peritoneal cavity. Since the time of auto PBSCT, the patient has remained without systemic treatment.
Discussion
The diagnosis of the POEMS syndrome may be difficult because in order to pronounce it seemingly separate symptoms must be combined into one entity. Moreover, POEMS patients present a remarkable diversity of symptoms, hence there exist controversies as to the minimal criteria for diagnosis [1, 2, 5] . One of the most recent suggestions concerning minimal diagnostic criteria includes the presence of two main symptoms i.e. polyneuropathy and monoclonal plasmaprolipherative disorder combined with at least one of the minor symptoms, such as sclerotic bone lesions, organomegaly, endocrinopthy, Castleman's disease, skin lesions, edema and effusions, papilledema [5] . The patient fulfilled both four main acronym criteria (P,O,E,M) and a number of minor ones.
A leading POEMS symptom is symmetrical, usually sensory-motor, polyneuropathy of a mixed axonal and demyelinizating type. In the case of our patient it was the main disorder present during the entire observation period, and one which had only subjectively improved after autologous PBSCT. The POEMS patients manifest a wide spectrum of polyneuropathy intensity -from parasthesias to generalized paresis and wheel-chair bound disability. Neuropathy symptoms progress slowly and usually resistant to standard treatment [1, 2, 5, 7, 8] .
An array of plasma cell dyscrasia in the course of the POEMS syndrome may range from a monoclonal gammopathy of unknown significance to overt myeloma with osteosclerotic or mixed sclerotic and osteolytic bone lesions [1, 2, 5, 6, 8] . In some rare situations this syndrome is associated with other lymphoplasmacytic neoplasms, such as Waldenström macroglobulinaemia [10] . During the 18-month treatment our patient demonstrated low and stable serum M protein IgGλ concentrations and low or normal plasma cell rate in the bone marrow. Auto PBSCT did not allow to decrease the M protein level. Low M protein concentration with a significant(up to 95% of cases) prevalence of the λ light chain type and low bone marrow plasmacytosis (considered non-diagnostic for myeloma) are common in POEMS [2, 5, 6, 8, 9] . Contrary to typically observed myeloma bone lesions, the patient presented with disseminate osteosclerotic lesions. In approximately 1% of multiple myeloma patients osteosclerotic changes are found [11] , while single, but more often disseminated, ostesclerotic or mixedosteosclerotic and osteolytic bone lesions are observed in almost all POEMS patients. On pathological examination plasma cell infiltrates may be discerned [2, 5, 6, 8] .
Limited splenomegaly and lymphadenopathy did not regress during treatment, as well as during the post autologous PBSCT observation. Organomegaly, especially splenomegaly, is found in 30-50% of cases, while the less common lymphadenopathy -in 25% of patients. Biopsy usually shows features of Castleman's disease [2, 5] .
Subclinical hypothyroidism was another feature observed in our patient; this abnormality together with disturbances of the gonadal axis may be considered to be the most frequent endocrinopathies observed in the course of the POEMS syndrome [2, 5] .
Extravascular volume overloading is also a typical feature of POEMS, initially in our patient it manifested itself only as leg edema and asymptomatic papilledema, but was later followed by slight ascites and pleural effusion. According to recent views these and other symptoms result from the overproduction of a number of cytokines such as IL-6, IL-1β, PDGF, TNFα and VEGF, which in turn is brought on by altered interactions between tumor plasma cells and their microenvironment [3-5, 8, 9] . Of these the VEGF seems to be causative for microangiopathy, increased vasopermeability, neovascularisation and the formation of skin angiomas, while its serum concentration correlates with symptom severity and response to treatment [4, 12] .
Generally, the treatment of POEMS mimics that administered in the case of plasma cell tumors. In localized tumors, such as single bone plasmacytoma, the removal of the lesion or the administration of radiotherapy result in long-term remission, including polyneuropathy regression [5, 8] . In systemic disease, various chemotherapy programs are used. Some authors report on the efficacy of prednisone, or mephalan and prednisone, and other combined anti-myeloma chemotherapy regimens, with most recent reports concerning the administration of thalidomide. There also exist reports concerning the application of other treatment modalities, such as plasmapheresis, intravenous immunoglobulins, immunospuressive drugs although these have shown to have limited or no efficacy [5, 9] . A relatively long survival with a median of 165 months in responding patients has been reported lately [5] .
The inefficacy of systemic chemotherapy, especially in the case of patients with widespread osteosclerotic lesions who were suffering from neurological complications, prompted the search for new treatment methods. Beginning with the year 2001, the authors of first reports on autologous bone marrow or PBSCT in POEMS patients following myeloablative treatment (sometimes preceded by total body irradiation or the application of the bone seeking isotope Samarium) had emphasized a significant long-term improvement, reaching even some 10 years, often associated with a dramatic regression of neurological symptoms and the disappearance of monoclonal protein [6] [7] [8] 12] . However, in the most recent and, so far, the largest single institution study on 16 patients undergoing auto PBSCT after previous unsuccessful treatment, the authors have reported one death during the peritransplant period, one case of long-term mechanical ventilation maintenance and five cases of respiratory failure requiring intubation. Thus the authors stress both the efficacy and the significant morbidity of this therapy [13] . In the case of our patient the initial VAD treatment did not result in neurological improvement. In turn, his peritransplant period was free from severe, life threatening events. The majority of POEMS symptoms persisted, but did not progress. It suggests that the entire treatment did not result in essential improvement but, rather, resulted in disease stabilization.
The rarity of this particular syndrome, the lack of established treatment methods and the limited experience with myeloablative treatment followed by autologous PBSCT has prompted us to report this case.
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